Clinical use of colistin induces cross-resistance to host antimicrobials in Acinetobacter baumannii

mBio

Volumn 4, Issue 3, 2013, Pages

  Napier, Brooke A ^a   Burd, Eileen M ^a   Satola, Sarah W ^a,b,c   Cagle, Stephanie M ^a,c   Ray, Susan M ^a,c,f   Mcgann, Patrick ^d   Pohl, Jan ^e   Lesho, Emil P ^d   Weiss, David S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c Walter Reed Army Institute of Research ^*

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f GRADY MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; COLISTIN; LYSOZYME; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG USE; HOST RESISTANCE; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PMRB GENE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; ACINETOBACTER INFECTIONS; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; BACTERIA (MICROORGANISMS); KLEBSIELLA PNEUMONIAE; PSEUDOMONAS AERUGINOSA;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; COLISTIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MURAMIDASE;

EID: 84879590434     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00021-13     Document Type: Article

References (24)

1. Brusselaers N, Vogelaers D, Blot S. 2011. The rising problem of antimicrobial resistance in the intensive care unit. Ann. Intensive Care 1:47.
2. de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, Icket C, Kalenic S, Horvatic J, Seifert H, Kaasch AJ, Paniara O, Argyropoulou A, Bompola M, Smyth E, Skally M, Raglio A, Dumpis U, Kelmere AM, Borg M, Xuereb D, Ghita MC, Noble M, Kolman J, Grabljevec S, Turner D, Lansbury L, Grundmann H, BURDEFN Study Group. 2011. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob. Agents Chemother. 55:1598-1605.
3. Maragakis LL, Perencevich EN, Cosgrove SE. 2008. Clinical and economic burden of antimicrobial resistance. Expert Rev. Anti Infect. Ther. 6:751-763.
4. Salgado CD, O'Grady N, Farr BM. 2005. Prevention and control of antimicrobial-resistant infections in intensive care patients. Crit. Care Med. 33:2373-2382.
5. Vandijck DM, Depaemelaere M, Labeau SO, Depuydt PO, Annemans L, Buyle FM, Oeyen S, Colpaert KE, Peleman RP, Blot SI, Decruyenaere JM. 2008. Daily cost of antimicrobial therapy in patients with intensive care unit-acquired, laboratory-confirmed bloodstream infection. Int. J. Antimicrob. Agents 31:161-165.
6. Dijkshoorn L, Nemec A, Seifert H. 2007. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol. 5:939-951.
7. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582.
8. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51:3471-3484.
9. Cai Y, Chai D, Wang R, Liang B, Bai N. 2012. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J. Antimicrob. Chemother. 67:1607-1615.
10. Hancock RE. 1997. Peptide antibiotics. Lancet 349:418-422.
11. Bucki R, Leszczyńska K, Namiot A, Sokołowski W. 2010. Cathelicidin LL-37: a multitask antimicrobial peptide. Arch. Immunol. Ther. Exp. (Warsz) 58:15-25.
12. Düring K, Porsch P, Mahn A, Brinkmann O, Gieffers W. 1999. The non-enzymatic microbicidal activity of lysozymes. FEBS Lett. 449:93-100.
13. Ibrahim HR, Thomas U, Pellegrini A. 2001. A helix-loop-helix peptide at the upper lip of the active site cleft of lysozyme confers potent antimicrobial activity with membrane permeabilization action. J. Biol. Chem. 276: 43767-43774.
14. Laible NJ, Germaine GR. 1985. Bactericidal activity of human lysozyme, muramidase-inactive lysozyme, and cationic polypeptides against Streptococcus sanguis and Streptococcus faecalis: inhibition by chitin oligosaccharides. Infect. Immun. 48:720-728.
15. Thennarasu S, Tan A, Penumatchu R, Shelburne CE, Heyl DL, Ramamoorthy A. 2010. Antimicrobial and membrane disrupting activities of a peptide derived from the human cathelicidin antimicrobial peptide LL37. Biophys. J. 98:248-257.
16. Vaara M, Vaara T. 1981. Outer membrane permeability barrier disruption by polymyxin in polymyxin-susceptible and-resistant Salmonella typhimurium. Antimicrob. Agents Chemother. 19:578-583.
17. Vandamme D, Landuyt B, Luyten W, Schoofs L. 2012. A comprehensive summary of LL-37, the factoctum human cathelicidin peptide. Cell. Immunol. 280:22-35.
18. Mai J, Tian XL, Gallant JW, Merkley N, Biswas Z, Syvitski R, Douglas SE, Ling J, Li YH. 2011. A novel target-specific, salt-resistant antimicrobial peptide against the cariogenic pathogen Streptococcus mutans. Antimicrob. Agents Chemother. 55:5205-5213.
19. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA. 2009. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53:3628-3634.
20. Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS, Hancock RE. 2011. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob. Agents Chemother. 55:3743-3751.
21. Lesho E, Yoon E, McGann P, Snesrud E, Kwak Y, Milillo M, OnmusLeone F, Preston L, St. Clair K, Nikolich M, Viscount H, Wortmann G, Zapor M, Grillot-Courvalin C, Courvalin P, Clifford R, Waterman P. Emergence of colistin-resistance in Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of extremely-drugresistant wound infections. J. Infect. Dis, in press.
22. Chen Z, Wang D, Cong Y, Wang J, Zhu J, Yang J, Hu Z, Hu X, Tan Y, Hu F, Rao X. 2011. Recombinant antimicrobial peptide hPAB-÷ expressed in pichia pastoris, a potential agent active against methicillinresistant Staphylococcus aureus. Appl. Microbiol. Biotechnol. 89: 281-291.
23. Lamb HM, Wiseman LR. 1998. Pexiganan acetate. Drugs 56:1047-1052; discussion 1053-1054.
24. Peters BM, Shirtliff ME, Jabra-Rizk MA. 2010. Antimicrobial peptides: primeval molecules or future drugs? PLoS Pathog. 6:e1001067.